Loading clinical trials...
Loading clinical trials...
Safety of Rapid-Infusion Isatuximab in Patients With Relapsed/Refractory Multiple Myeloma
Conditions
Interventions
Rapid Infusion Isatuximab
Start Date
May 28, 2021
Primary Completion Date
November 30, 2022
Completion Date
December 31, 2022
Last Updated
July 7, 2022
NCT04973605
NCT06138275
NCT05862012
NCT06285318
NCT07284758
NCT07391657
Lead Sponsor
Thomas Martin, MD
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions